COVID-19 Vaccination Intention in Patients with Autoimmune Diseases in Indonesia: An Application of the Integrated Behavioural Model

Widhani, Alvina; Pelupessy, Dicky; Siddiq, Tommy Hariman; Koesnoe, Sukamto; Maria, Suzy; Yunihastuti, Evy; Awanis, Ghina Shabrina; Karjadi, Teguh Harjono; Hasibuan, Anshari Saifuddin; Sukmana, Nanang; Hakam, Mulki; Putri, Kartika Qonita; Taufik, Insy Nafisah; Widiyanti, Delina; Rengganis, Iris; Djauzi, Samsuridjal

doi:10.3390/tropicalmed8020109

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 However, only 42.4% of autoimmune disease patients in Indonesia received COVID-19 vaccination. 24 In line with this, our study's immunization rate of only 49.0% was much lower than the Chinese overall population vaccination rate of 90.6%.…”

Section: Discussionsupporting

confidence: 76%

Efficacy and safety of inactivated SARS‐CoV‐2 vaccination in COVID‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study

Liu,

Jin,

Feng

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

ObjectivesTo identify the effectiveness and safety of inactivated SARS‐CoV‐2 vaccines in rheumatic and musculoskeletal diseases (RMDs) patients.MethodsRMD patients with COVID‐19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID‐19‐associated pneumonia was the primary outcome. The effect of COVID‐19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated.ResultsAmong 592 RMD patients with COVID‐19, 276 (46.6%) individuals experienced COVID‐19‐associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID‐19‐associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID‐19‐associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41–0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34–0.83), and who have lung involvement (OR 0.43, 95% CI 0.23–0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred.ConclusionInactivated COVID‐19 vaccines were safe and effective in reducing the risk of COVID‐19‐associated pneumonia of RMD patients in China.

show abstract

Section: Discussionsupporting

confidence: 76%

Efficacy and safety of inactivated SARS‐CoV‐2 vaccination in COVID‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study

Liu,

Jin,

Feng

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…A qualitative study on understanding influenza pandemic based on rural community in Central Java found mixed opinions about Avian Flu as a rumor that have influenced their trust with the government's program to prevent Avian Flu cases [14]. To our knowledge, there have been limited evidence on risk perception, barriers and motivating factors that influencing the adoption of preventive measures towards COVID-19 in the context of Indonesia [15]. In order to fill this gap, a qualitative study was conducted to explore perception and factors underlying responses among adults in taking preventive measures towards COVID-19 in Indonesia.…”

Section: Introductionmentioning

confidence: 99%

A Qualitative Study with Health Belief Model: Perceived Risks and Compliance Towards COVID-19 Prevention Measures Among Adults in Indonesia

Ipa¹,

Dhewantara²,

Pardosi³

et al. 2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

Current policy responses in Indonesia have been focused on increasing public awareness of the risks of COVID-19. Nevertheless, there is limited information concerning public perceptions on COVID-19 pandemic that would contribute for formulating adequate preventative approaches to mitigate consequences of COVID-19 in the population. The Health Belief Model (HBM) approach was adopted in this qualitative study among Indonesian adults in 34 provinces. Risks and barriers perception of COVID-19 prevention measures were assessed include exploring perceived of susceptibility, perceived of severity, perceived of benefits and perceived barriers. In-depth interviews (IDIs) were performed in April 2020 via phone (online interview). Thematic analysis approach was applied for the qualitative data analysis. The findings suggests that perception towards COVID-19 has influenced level of participation and compliance in practicing recommended preventive and control measures. Several obstacles to implement the preventive measures included the readiness of the government in terms of infrastructure and human resources for health. Lacking in terms of complying with prevention policies and health protocols, and overlapping policies launched by the government felt by the public were found to create mixed messages and responses on adequate preventative measures relating to COVID-19 epidemics situation in Indonesia. Of which, in the context of global crisis a consistent regulation and firmness in implemented related issues play a crucial role in forming participatory of preventive and control measures. Persistent and assertiveness of policy responses can increase and sustain community trust as well as their attitudes and compliance with COVID-19 preventive measures for preventing community transmission of COVID-19.

show abstract

“…However, during this study, little was known about the vaccine response in individuals with autoimmune rheumatic diseases and if they would mount an adequate immune response. Patients also expressed concerns about the vaccine’s potential impact on their immune system and whether it could trigger a flare-up of their condition [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines

Dey,

Katso,

Amoako

et al. 2024

BMC Rheumatol

View full text Add to dashboard Cite

Background Vaccines are a crucial component of the global efforts to control the spread of COVID-19. Very little is known about COVID-19 vaccine responses in patients living with autoimmune rheumatic conditions in Africa. We examined the clinical reaction to COVID-19 vaccinations in Ghanaians diagnosed with autoimmune rheumatic disease. Methods This was a hospital-based interventional cohort study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients recruited via regular face-to-face clinic visits. The systemic lupus erythematosus disease activity index Selena modification (SELENA-SLEDAI) and the disease activity score 28-joint count-erythrocyte sedimentation rate (DAS28-ESR) were used to measure changes in disease activity levels. Results Thirty-eight (38) patients of which 21 (55.3%) were diagnosed with SLE and 17 (44.7%) with RA contributed data for analyses. Most (89.5%) of the patients were females, with a mean age of 37.4 years. The SLE patients experienced a notable increase in severe flares during weeks three and six, as well as the third and sixth months, followed by subsequent decreases in the twelfth month, while remission levels increased throughout the same period. Among RA patients, high disease activity decreased during weeks three and six, as well as the third, sixth, and twelfth months, with remission levels increasing during the same time. A low dose (≥ 50 < 75 mg) dose of azathioprine was at some point associated with having a severe flare among SLE patients. After both vaccine doses, SLE patients were the majority having experienced both local and systemic reactions, all resolving within 24 h. Approximately 73.7% of the patients were COVID-19 negative at baseline. During post-vaccination visits, this increased to 100% by week six, with no positives thereafter. Conclusion This study explores COVID-19 vaccine responses in Ghanaian autoimmune rheumatic disease patients, revealing disease activity levels in RA patients improved after vaccination compared to SLE patients. Our findings identify a potential link between low-dose azathioprine and severe flares in SLE patients, particularly evident in the third-week post-vaccination. Further research is warranted to clarify these findings and guide tailored treatment approaches in this medically significant population during pandemics and vaccination efforts.

show abstract

COVID-19 Vaccination Intention in Patients with Autoimmune Diseases in Indonesia: An Application of the Integrated Behavioural Model

Cited by 3 publications

References 20 publications

Efficacy and safety of inactivated SARS‐CoV‐2 vaccination in COVID‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study

Efficacy and safety of inactivated SARS‐CoV‐2 vaccination in COVID‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study

A Qualitative Study with Health Belief Model: Perceived Risks and Compliance Towards COVID-19 Prevention Measures Among Adults in Indonesia

Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines

Contact Info

Product

Resources

About